CRBU · NASDAQ
Caribou Biosciences (CRBU) Stock Price & Fundamentals
Caribou Biosciences (CRBU) closed at $887.17 on Oct 9, 2026, down 1.44% from the previous close of $900.12.
Share price, past year
1Y +23.75%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $887.17 |
| Sep 30, 2026 | $891.31 |
| Aug 31, 2026 | $880.68 |
| Jul 31, 2026 | $925.60 |
| Jun 30, 2026 | $870.34 |
| May 29, 2026 | $794.48 |
| Apr 30, 2026 | $795.68 |
| Mar 31, 2026 | $788.37 |
| Feb 27, 2026 | $781.43 |
| Jan 30, 2026 | $745.62 |
| Dec 31, 2025 | $758.47 |
| Nov 28, 2025 | $787.64 |
| Oct 31, 2025 | $701.23 |
Key statistics
- Market cap
- $94.04B
- P/E (TTM)
- —
- EPS (TTM)
- −$1.08
- Revenue (TTM)
- $10.04M
- Net income (TTM)
- −$103.40M
- Shares outstanding
- 106M
- Dividend yield
- —
- 52-week range
- $701.23 – $930.30
Caribou Biosciences's market cap is $94.04B, based on a share price of $887.17 and 106M shares outstanding as of Jun 30, 2026.
Financials
Caribou Biosciences reported revenue of $11.16M for fiscal 2025, up 11.66% from fiscal 2024.
Caribou Biosciences reported a net loss of $148.13M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $11.16M | +11.7% | −$148.13M | −1,327.4% | −$1.59 | −$112.35M |
| FY2024ended Dec 31, 2024 | $9.99M | −71.0% | −$149.11M | −1,492.0% | −$1.65 | −$143.08M |
| FY2023ended Dec 31, 2023 | $34.48M | +148.9% | −$102.07M | −296.1% | −$1.38 | −$104.90M |
| FY2022ended Dec 31, 2022 | $13.85M | +44.3% | −$99.42M | −717.8% | −$1.64 | −$97.42M |
| FY2021ended Dec 31, 2021 | $9.60M | −22.4% | −$66.92M | −697.3% | −$2.11 | −$34.64M |
| FY2020ended Dec 31, 2020 | $12.36M | +113.6% | −$34.31M | −277.6% | −$4.01 | −$33.53M |
| FY2019ended Dec 31, 2019 | $5.79M | — | −$23.43M | −404.8% | −$2.80 | −$32.89M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $1.50M | −$24.28M | −$0.24 |
| Q1 FY2026ended Mar 31, 2026 | $2.40M | −$25.09M | −$0.26 |
| Q4 FY2025ended Dec 31, 2025 | $3.94M | −$26.49M | −$0.28 |
| Q3 FY2025ended Sep 30, 2025 | $2.20M | −$27.55M | −$0.30 |
| Q2 FY2025ended Jun 30, 2025 | $2.67M | −$54.10M | −$0.58 |
| Q1 FY2025ended Mar 31, 2025 | $2.35M | −$39.99M | −$0.43 |
| Q4 FY2024ended Dec 31, 2024 | $2.08M | −$35.49M | −$0.39 |
| Q3 FY2024ended Sep 30, 2024 | $2.02M | −$34.68M | −$0.38 |
Company profile
- Name
- Caribou Biosciences, Inc.
- Ticker
- CRBU
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Biological Products, (No Diagnostic Substances)
- Headquarters
- 2929 7th Street, Suite 105, Berkeley, CA 94710
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001619856
Recent SEC filings
- Oct 6, 2026
- Aug 13, 2026
- Aug 13, 2026
- Jun 18, 2026
- Jun 11, 2026
- May 7, 2026
- May 7, 2026
- Mar 31, 2026
Frequently asked questions
What is Caribou Biosciences's stock price?
Caribou Biosciences (CRBU) closed at $887.17 on Oct 9, 2026, down 1.44% from the previous close of $900.12.
What is Caribou Biosciences's market cap?
Caribou Biosciences's market cap is $94.04B, based on a share price of $887.17 and 106M shares outstanding as of Jun 30, 2026.
How much revenue does Caribou Biosciences make?
Caribou Biosciences reported revenue of $11.16M for fiscal 2025, up 11.66% from fiscal 2024.
Does Caribou Biosciences pay a dividend?
Caribou Biosciences's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Caribou Biosciences, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures